

Intellectual Property Activities


Intellectual Property Activities

New Medium-term Plan and Governance System

The Intellectual Property Function has formulated a new medium-term plan that complements the new company strategy announced by Olympus in May 2023. We are now working to implement this plan approved by management.

In 2021, the Intellectual Property Function was reorganized as part of the Global Legal Organization. It also has reporting lines to the R&D functions that are the source of new inventions. Under this organizational structure, we are working to enhance our intellectual property (IP) investment initiatives with the aim of driving innovation over the medium- to long-term future by optimizing our IP activities through feedback from regular discussions with the Chief Technology Officer (CTO). Furthermore, the Global General Counsel reports on activities to the Board of Directors once a year and the Intellectual Property function takes appropriate measures as necessary.

Through these measures, we have created a structure that allows Olympus management to monitor the Company's IP activities. In addition, we are working under the aforementioned medium-term plan to establish a system that complies with the international standard for IP management (ISO 56005), as part of our efforts to strengthen our governance structure.



Growth-oriented IP Investment Based on Characteristics of the Medical Business Environment

Following the transfer of the Scientific Solutions Business in April 2023, our IP investment focuses on the Medical Business, especially the Endoscopic Solutions Business and Therapeutic Solutions Business. Our goal is to use patent applications to maintain our competitive edge in the Endoscopic Solutions Business area and to establish a competitive advantage for the Therapeutic Solutions Business, which has become a growth driver for Olympus. To achieve our competitive advantage strategically and efficiently, we have introduced a business process under which decisions about the allocation of patent application investment are made through discussions with the Endoscopic Solutions Business and Therapeutic Solutions Business, based on an overview of all projects that have been approved for these businesses through our strategic business plan. By establishing specialist units to provide cross-regional management of the patent portfolios of the Endoscopic Solutions Business and Therapeutic Solutions Business, we have also created a structure capable of centrally managing our patent portfolio on a global basis. In addition, we are strengthening our IP

capabilities to support the specialized business development function that we have established in the United States from a due diligence perspective, with a view to future expansion of our patent portfolio through M&A activities.

Through careful alignment with our strategy and by shifting our investment toward high-growth areas, we are continuing to enhance the "strength" of each individual patent and therethrough rapidly closing the gap on our European and American competitors. We will continue our efforts to establish a patent portfolio that will contribute to Olympus' sustainable growth.

Patents Held by Olympus (Approx. 16,000*1)



*1 As of March 2023. Excluding Scientific Solutions Business

Using IP Intelligence for Care Pathway Enhancement

In 2022, our dedicated patent analysis team helped more than 20 Olympus units to develop business strategies by providing

IP landscapes that incorporate IP information into their business information to provide a comprehensive overview of

their current statuses and future outlooks. Following our company strategy on Care Pathway Enhancement, we continue our analyses of business environments around diseases from the perspective of the respective entire care pathway (from early detection to post procedure).

This approach allows us to gain insights about care

pathways, especially in contributing to a deeper understanding of new areas other than diagnosis and treatment. Our focus now is to reflect the knowledge obtained through these business environment analyses in high-level planning, including disease strategies and technology roadmaps.

Enhance Cross-regional and Cross-functional IP Capabilities

The regional organizations of the Intellectual Property Function work together to pursue global product development initiatives and projects spanning multiple regions. We aim to improve quality, streamline management, and reduce costs globally by standardizing and integrating work processes and project management systems that have traditionally varied from region to region.


In addition to training within the Intellectual Property Function, we are also strengthening IP capabilities across multiple regions and departments by providing IP training

globally to business units and R&D functions. For example, we provide business units with programs designed to enhance IP literacy, which is vital for strategic planning and other processes. For R&D functions, we offer programs designed to improve the quality of their invention proposals.

As part of our company strategy, we are also integrating business processes and regulations to create a governance structure that will enable companies acquired through M&A to work organically with Olympus' Intellectual Property function.


Analysis of Patent Score*2 Relative to Competitors

Overall, Olympus is rapidly improving its average patent score (strength) per patent.




*2 An indicator that determines the quality and value of patents automatically, objectively, and quantitatively. Source: Calculated using Anaqua's AcclaimIP Patent Score method

The Endoscopic Solutions Business has a competitive edge over its competitors, and we are ensuring that this will be maintained.



The Therapeutic Solutions Business will accelerate its efforts to acquire stronger patents so that it can shift to the upper right of the graph as business scale grows.



Bubble size: Average patent score